CCHT(SZ:000661) Shang Hai Zheng Quan Bao·2025-09-05 21:40Group 1 - The core announcement is that Changchun High-tech Industry (Group) Co., Ltd.'s subsidiary, Changchun JinSai Pharmaceutical Co., Ltd., has received acceptance for the clinical trial application of the injectable GenSci140 from the National Medical Products Administration [1][2] - GenSci140 is a novel dual-target antibody-drug conjugate specifically designed to target the folate receptor alpha (FRα), which is expressed in various tumors, including ovarian cancer [2][3] - The drug utilizes a unique linker technology and is expected to enhance tumor cell killing while maintaining a favorable safety profile, making it a potential best treatment option for FRα-positive cancer patients, particularly those with low to medium expression levels [3] Group 2 - If the clinical trial progresses smoothly, it will help the company expand its business scope, optimize its product structure, and enhance its core competitiveness [4] - The pharmaceutical product development process is characterized by high technology, high risk, and long timelines, which may be influenced by various uncertainties [4][5] - The company will actively promote the research and development of this project and fulfill its information disclosure obligations regarding subsequent progress [5]